Biolegend, 115539, Brilliant Violet 605™ anti-mouse CD19 Antibody, 125microl

CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse CD19-expressing K562 human erythroleukemia cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence7.
Application References(PubMed link indicates BioLegend citation): Shoham T, et al. 2003. J. Immunol. 171:4062. (FC) Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. (FC) Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC) Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed Olive V, et al. 2013. Elife. 2:822. PubMed Miyai T, et al. 2014. PNAS. 111:11780. PubMed
Product Citations: Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed Arruda DC, et al. 2022. J Control Release. 350:228. PubMed Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed Rege SV, et al. 2023. Commun Biol. 6:292. PubMed Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed Collin R, et al. 2020. J Immunol. 205:133. PubMed Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed Kim E, et al. 2022. Immunity. 55:145. PubMed Paik D, et al. 2022. Nature. 603:907. PubMed Xiong E, et al. 2023. Front Immunol. 13:1083119. PubMed Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed John S, et al. 2020. Sci Rep. 10:11377. PubMed Gawish R, et al. 2022. Elife. 11:. PubMed Pokrovskii M, et al. 2019. Immunity. 51:185. PubMed Earnest JT, et al. 2021. Cell Reports. 35(1):108962. PubMed Benhamou D, et al. 2018. Front Immunol. 2.260416667. PubMed Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed Maisonneuve C, et al. 2021. Cell Reports. 34(4):108677. PubMed Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed Zhang R, et al. 2021. MAbs. 13:1904546. PubMed Hutter K, et al. 2020. FEBS J. . PubMed Li J, et al. 2018. Immunity. 49:178. PubMed Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed White JM, et al. 2020. Mol Pharm. 2.165972222. PubMed Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed Van Winkle JA et al. 2018. Cell host & microbe. 24(5):665-676 . PubMed Alameh MG, et al. 2021. Immunity. 54:2877. PubMed Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed Colliou N, et al. 2015. Toxins. 7: 3805 - 3817. PubMed Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed Kitajima Y, et al. 2022. Cells. 11:. PubMed Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed Yousef H, et al. 2019. Nat Med. 25:988. PubMed Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed Subramaniam N, et al. 2021. Blood Adv. 5:1259. PubMed Heil J, et al. 2021. Nat Commun. 12:6963. PubMed Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed Teng F, et al. 2021. Cell Rep. 37:110051. PubMed Tummala G, et al. 2021. Invest Ophthalmol Vis Sci. 62:41. PubMed Bramwell K, et al. 2015. J Immunol. 195: 1647 - 1656. PubMed Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed Parigger T, et al. 2021. Int J Mol Sci. 22:. PubMed Nascimento DC, et al. 2021. Immunity. :. PubMed Laczkó D, et al. 2020. Immunity. 53:724. PubMed Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
RRID: AB_11203538 (BioLegend Cat. No. 115539) AB_2563067 (BioLegend Cat. No. 115540)
Structure: Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution: Pro-B cells to mature B cells (during development), follicular dendritic cells
Function: Modulates B cell activation and differentiation
Ligand/Receptor: CD21, CD81, Leu-13
Cell Type: B cells, Dendritic cells
Biology Area: Costimulatory Molecules, Immunology
Molecular Family: CD Molecules
Antigen References: 1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341. 2. Krop I, et al. 1996. Eur. J. Immunol. 26:238. 3. Krop I, et al. 1996. J. Immunol. 157:48. 4. Tedder TF, et al. 1994. Immunol. Today 15:437.
Gene ID: 12478
UniProt: View information about CD19 on UniProt.org
Clone: 6D5
Regulatory Status: RUO
Other Names: B4
Isotype: Rat IgG2a, κ